Search Results
Found 4 results for "austria" across articles, medicines, trials, companies and the glossary
Regulatory Affairs
Addressing the 801-Day Lag: Ireland’s Drug Approval System Demands Urgent Structural Reform
The latest EFPIA Patients W.A.I.T. Indicator report reveals that Irish patients wait an average of 801 days to access newly approved medicines, prompting calls for an overhaul of the HSE and NCPE reimbursement processes and a dedicated mechanism for rare disease orphan drugs.
Pharmaceutical
The Cascade Effect: How US MFN and IRA Pricing Mandates Are Reshaping Drug Development, Launch Sequencing, and Ireland’s Life Sciences Sector
An in-depth analysis of how US Most Favored Nation (MFN) drug pricing proposals and the Inflation Reduction Act (IRA) are forcing pharmaceutical companies to restructure indication sequencing, ex-US launches, and global supply chains.
Regulatory Affairs
How Most Favored Nation (MFN) Pricing Impacts Drug Development & Launch Planning
An expert analysis of the strategic shifts required in global drug development, indication sequencing, and launch timelines in response to proposed Most Favored Nation pricing and the Inflation Reduction Act.
Industry
Europe's United Front: How the Beneluxa Initiative is Defending the Pharma Framework Against US Pricing Pressure
With the US pushing for individual drug pricing deals and Germany slashing healthcare spending, the Beneluxa Initiative represents five European nations calling for a unified, coordinated approach to protect Europe's pharmaceutical innovation and access to medicines in 2026.